OGN: Organon & Co. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 5,395.44
Enterprise Value ($M) 13,534.44
Book Value ($M) -70.00
Book Value / Share -0.27
Price / Book -77.08
NCAV ($M) -7,647.00
NCAV / Share -29.74
Price / NCAV -0.71

Profitability (mra)
Return on Invested Capital (ROIC) 0.12
Return on Assets (ROA) 0.10
Return on Equity (ROE) n/a

Liquidity (mrq)
Quick Ratio 1.15
Current Ratio 1.65

Balance Sheet (mrq) ($M)
Current Assets 4,196.00
Assets 11,891.00
Liabilities 11,843.00
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 6,263.00
Operating Income 1,564.00
Net Income 1,023.00

Cash Flow Statement (mra) ($M)
Cash From Operations 799.00
Cash from Investing -260.00
Cash from Financing -569.00

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)
Change
(%)
02-13 13G/A Vanguard Group Inc 11.97 -2.78
02-05 13G/A Mawer Investment Management Ltd. 0.00 -100.00
01-25 13G/A State Street Corp 3.72 -26.09
01-23 13G/A BlackRock Inc. 13.10 3.38

Top 13F Investors Shares
(1000)
Change
(%)
Value
($1000)
Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-05-03 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT P
2024-02-26 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K
2023-11-03 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 ☐ TRANSITION REPO
2023-08-09 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 ☐ TRANSITION REPORT PU

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2024-05-29 188,712 1,187,480 15.89
2024-05-28 142,936 952,580 15.01
2024-05-24 140,681 1,043,753 13.48

(click for more detail)

Similar Companies
LLY – Eli Lilly and Company MRK – Merck & Co., Inc.
NUVB – Nuvation Bio Inc. PBH – Prestige Consumer Healthcare Inc.
PFE – Pfizer Inc.


Financial data and stock pages provided by
Fintel.io